ABEO Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: As of September 30, 2025, ABEO reported cash, cash equivalents, restricted cash, and short-term investments totaling $207.5 million, providing over two years of operational funding without anticipated revenue from ZivaSkin.

R&D Expenses: Decreased to $4.2 million for Q3 2025 from $8.9 million in Q3 2024, primarily due to capitalized costs.

SG&A Expenses: Increased to $19.3 million from $6.4 million in Q3 2024, reflecting reclassification of expenses and increased costs associated with the ZivaSkin launch.

Net Loss: Reported at $5.2 million (negative $0.10 per share), significantly improved from a net loss of $30.3 million (negative $0.60 per share) in the prior year.

2Strategic Updates and Business Highlights

ZivaSkin Launch: The launch of ZivaSkin, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), is progressing despite a delay in the first patient treatment, now expected in 2025 due to optimization of a product release assay.

Patient Demand: Identified eligible patients have more than doubled from 12 to approximately 30, with strong demand and ongoing patient referrals to qualified treatment centers (QTCs).

QTC Expansion: Activated a new QTC at Children's Hospital Colorado, bringing the total to three centers, with ongoing discussions to expand further.

Market Access: Positive coverage decisions from major commercial payers and Medicaid programs have been established, covering over 80% of commercially insured lives. A permanent product J code from CMS is set to take effect on January 1, 2026.

3Forward Guidance and Outlook

ABEO maintains its guidance for achieving profitability in the first half of 2026, unaffected by the delay in patient treatment.

The company is optimistic about the ZivaSkin launch, anticipating a strong start in 2026 as patient treatments commence.

4Bad News, Challenges, or Points of Concern

Delay in Patient Treatment: The first patient treatment has been postponed to 2025 due to assay optimization issues, which could impact initial revenue recognition timelines.

Operational Challenges: A temporary pause in patient biopsy collection was implemented to address quality control issues, although this has since been resolved.

Plant Shutdown: A routine maintenance shutdown of the manufacturing plant is scheduled for mid-December, which could affect production timelines.

5Notable Q&A Insights

Treatment Timeline: Patients with ZivaSkin product order forms are expected to receive treatment in 2026, with some already scheduled for biopsies.

Prior Authorization Process: The process involves clinical and financial approvals, with most payers following clinical trial criteria for coverage.

Patient Conversion Rates: High conversion rates are expected for patients with ZivaSkin product order forms, as these patients are motivated and already engaged in the treatment process.

Competitive Landscape: Many patients are currently on other therapies (e.g., VYJUVEC), indicating a competitive market but also a potential for ZivaSkin to fulfill unmet needs. Overall, while ABEO faces some operational challenges and delays, the company is positioned for a promising launch of ZivaSkin with strong market access and growing patient demand.